Fitzgerald R C, Saeed I T, Khoo D, Farthing M J, Burnham W R
Havering Hospitals NHS Trust, Romford, Essex, UK.
Dig Dis Sci. 2001 Sep;46(9):1892-8. doi: 10.1023/a:1010678913481.
Esophageal adenocarcinoma is increasing in incidence and has a high mortality unless detected early. Barrett's esophagus is the only known risk factor for this cancer; however, whether endoscopic surveillance reduces morbidity and mortality is controversial. Endoscopic cancer surveillance programes for Barrett's esophagus are not routinely practiced in the UK, and this is the first study to examine whether a rigorous surveillance protocol increases the detection rate of early oesophageal cancer. All patients with a diagnosis of Barrett's esophagus or associated adenocarcinoma attending Havering Hospitals NHS Trust between 1992 and 1998 were included. A retrospective analysis was made of patients undergoing informal surveillance (96 patients, 1992-1997) and a prospective analysis was conducted following the implementation of a rigorous protocol (108 patients, 1997-1998). Over the same time periods Barrett's associated cancers diagnosed in patients not undergoing surveillance were analyzed (262 patients 1992-1997, 98 patients 1997-1998). From 1992 to 1997, one case of high-grade dysplasia was detected (N = 96, 1%). From 1997 to 1998, two cancers and three high-grade dysplasias were detected during rigorous surveillance (N = 108, 4.6%). Three of these patients have had curative esophagectomies (one high-grade dysplasia and two T1,N0,M0 tumors). In 1992-1997, 10 patients were found to have cancer in previously undiagnosed Barrett's esophagus (N = 262, 3.8%). Of 3/10 cancers treated surgically, one patient had a curative procedure (T1,N0,M0). In 1997-1998, nine patients were found to have de novo Barrett's esophagus cancer (N = 88, 10.2%) and three had curative resections (T1,N0,M0). Two of the patients with T1 lesions had no endoscopic evidence of cancer but were detected as a result of the multiple biopsy protocol. In conclusion, a rigorous biopsy protocol increases the detection of early cancer in Barrett's esophagus.
食管腺癌的发病率正在上升,除非早期发现,否则死亡率很高。巴雷特食管是这种癌症唯一已知的危险因素;然而,内镜监测是否能降低发病率和死亡率仍存在争议。在英国,针对巴雷特食管的内镜癌症监测项目并未常规开展,而这是第一项研究严格监测方案是否能提高早期食管癌检出率的研究。纳入了1992年至1998年间在哈弗林医院国民保健服务信托基金就诊且诊断为巴雷特食管或相关腺癌的所有患者。对接受非正式监测的患者(96例,1992 - 1997年)进行回顾性分析,并在实施严格方案后进行前瞻性分析(108例,1997 - 1998年)。同时分析了未接受监测患者中诊断出的巴雷特相关癌症(1992 - 1997年262例患者,1997 - 1998年98例患者)。1992年至1997年,检测到1例高级别异型增生(N = 96,1%)。1997年至1998年,在严格监测期间检测到2例癌症和3例高级别异型增生(N = 108,4.6%)。其中3例患者接受了根治性食管切除术(1例高级别异型增生和2例T1、N0、M0肿瘤)。1992 - 1997年,在先前未诊断出的巴雷特食管中发现10例癌症(N = 262,3.8%)。在接受手术治疗的10例癌症中,1例患者接受了根治性手术(T1、N0、M0)。1997 - 1998年,9例患者被发现患有新发巴雷特食管癌(N = 88,10.2%),3例接受了根治性切除术(T1、N0、M0)。2例T1期病变患者内镜检查无癌症证据,但通过多次活检方案被检测出来。总之,严格的活检方案提高了巴雷特食管早期癌症的检出率。